SCHEMBL18384542

SCHEMBL18384542

COc1c2cnccc2c(OC)c2sc(CO)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.38
▸ HSD17B10 Q99714 2/20 0.34
▸ ICAM1 P05362 1/20 0.34
▸ SELE P16581 1/20 0.34
▸ CYP2A6 P11509 2/20 0.33
▸ CHUK O15111 2/20 0.33
▸ CYP11B1 P15538 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ GLA P06280 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ RCE1 Q9Y256 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32
▸ ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18384610 1.00 MAOA (0.38) MAOAHSD17B10ICAM1SELECYP2A6
SCHEMBL18384572 0.86 MAOA (0.38) MAOACYP2A6CHUKKDM4EALDH1A1
SCHEMBL18384590 0.79 MAOA (0.41) MAOAHSD17B10CHUKCYP11B1CYP11B2
SCHEMBL18384607 0.78 MAOA (0.33) MAOACYP2A6GAA
SCHEMBL18384571 0.78 MAOA (0.33) MAOACYP2A6GAA
SCHEMBL18473250 0.78 MAOA (0.38) MAOAHSD17B10CHUKKDM4EALDH1A1
SCHEMBL18384591 0.77 KDM4E (0.39) MAOAHSD17B10ICAM1SELEKDM4E
SCHEMBL18384600 0.77 CCNC (0.39) MAOAHSD17B10ICAM1SELECYP2A6
SCHEMBL18384538 0.77 MAOA (0.38) MAOAHSD17B10CHUKKDM4EALDH1A1
SCHEMBL18384537 0.77 CCNC (0.39) MAOAHSD17B10ICAM1SELECYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934309-B2 Tricyclic quinone derivative SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-03-02 — — US disclosed
US-20190241583-A1 NEW TRICYCLIC QUINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. 2019-08-08 — — US disclosed
EP-3127907-A1 NEW TRICYCLIC QUINONE DERIVATIVE Boston Biomedical, Inc. (US) 2017-02-08 — — EP disclosed
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE BOSTON BIOMEDICAL, INC. (US) 2017-01-19 — — US disclosed
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE BOSTON BIOMEDICAL, INC. (US) 2017-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241583-A1 NEW TRICYCLIC QUINONE DERIVATIVE NQO1, SQOR, SULT1E1 MAOA 599/4885HSD17B10 340/4885ICAM1 4380/4885
US-20170015677-A1 NEW TRICYCLIC QUINONE DERIVATIVE NQO1, SQOR, SULT1E1 MAOA 599/4885HSD17B10 340/4885ICAM1 4380/4885
US-10934309-B2 Tricyclic quinone derivative NQO1, NQO2, SQOR MAOA 540/4885HSD17B10 421/4885ICAM1 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback